Talk:Johnson & Johnson/Archives/2023

Updating History and removing duplicate content
Hi, I came up with some ways we can improve the article and reduce its size at the same time. Overall, the second half of the history is not compliant with Wikipedia policy, and the Covid-19 Vaccine section has grown out of control. Below is my research and suggestions to the content. What are your thoughts?--Chefmikesf (talk) 19:57, 3 October 2022 (UTC)


 * Hi,, I think I made the revisions you requested, but I wasn't sure whether the section "Coronavirus (COVID-19) response" was to be deleted from the J&J article or the Janssen COVID-19 vaccine article. Let me know if it needs to be re-inserted in J&J and deleted from Janssen? — Grand&#39;mere Eugene (talk) 00:34, 4 October 2022 (UTC)


 * Hi, I think the "Coronavirus (COVID-19) response" section is appropriate for the main JNJ article so you could add it back. Thanks! While I was researching all these sources I noticed the JNJ Template Box is out of date and Alex Gorsky's article has a flag and is in pretty rough shape. I updated two sandboxes with suggested edits Here and Here. Is this something you'd be open to review? If so, how would you suggest presenting the changes? Best--Chefmikesf (talk) 19:38, 5 October 2022 (UTC)
 * Hi Grand'mere Eugene Thanks for the update to the response section. I just wanted to check if the other requests are something you're interested in or should I reach out to others within the community? Best--~ Chefmikesf (talk) 17:36, 12 October 2022 (UTC)
 * Wow, Thanks for your help Grand'mere Eugene ! I noticed the template box edits were reverted; do you need sources or additional verification to publish them?--~ Chefmikesf (talk) 22:20, 12 October 2022 (UTC)
 * You're welcome— I'm still copy editing the Gorsky bio, mostly cleanup and adding links. Just now I made a few updates to that infobox, but I'm not aware of any reversion there or on the J&J article??
 * We do need a source for Gorsky birth date, unless you would prefer to use only his birth year, which is actually my preference for living subjects, for security/privacy reasons. (The rule is any fact in the infobox needs to be sourced in the main article. There are multiple reliable sources with his YOB, but I've not found anything on Ancestry.com that is a usable WP:RS.)
 * Let me know about other proposed infobox revisions.
 * I made one attempt to revise the J&J template, but didn't have enough time to sort out what went wrong with the formatting and it slipped my mind. I'll take another look this evening. — Grand&#39;mere Eugene (talk) 23:00, 12 October 2022 (UTC)
 * I finally was able to make the revisions to the J&J template. I did alphabetise some of the groups by the way each link displays (rather than by the linked article) and resolved a few disambiguation links. Should each section be alphabetised? — Grand&#39;mere Eugene (talk) 17:10, 13 October 2022 (UTC)
 * Hi Grand'mere Eugene, I can't find a source for his birth date so we can go with just the year. The updates look good to me, I just added to your work and added his biography to the external links section. I'm also working a different photo for the article so I'll let you know when that clears Wikimedia Commons.--Chefmikesf (talk) 17:51, 20 October 2022 (UTC)

1.

Reason and Request: The current history section is poorly sourced, has many outdated forward-facing statements, and the subsections are hard to understand. The new proposed section matches the style of the early history, includes encyclopedic events from the company's history, and removes uncited content to help with WP:Wikipedia:Article size issue. Please update the History 1943-present.

Existing Content Sections:
 * 1.5 1959: McNeil Consumer Healthcare
 * 1.6 1959: Cilag
 * 1.7 1961: Janssen Pharmaceuticals
 * 1.8 1998: DePuy Synthes
 * 1.9 1999: Janssen Biotech, Inc.
 * 1.10 Ethicon, Inc.
 * 1.10.1 Ethicon Endo-Surgery, Inc.
 * 1.11 2010 onwards

Proposed History 1943-present update

1943: Credo and going public
In 1943, as the company was preparing for its initial public offering (IPO), Robert Wood Johnson wrote what the company would call, "Our Credo", a defining document that has been used to guide the company's decisions over the years. The company completed its IPO and became a public company in 1944.

In 1943, Vesta Stoudt identified a need for waterproof tape for ammunition boxes in World War Two. She wrote to Franklin D. Roosevelt with the idea; the president commissioned Revolite, a subsidiary of Johnson & Johnson at the time, to develop and manufacture a cloth-based adhesive tape.

1944-1999: Acquisitions and international expansion
In 1944, the company began selling Johnson's Baby Lotion. The same year, the company established Ethicon Suture Laboratories. In 1947, G. F. Merson Ltd. was acquired to expand the company’s suture business in the United Kingdom. The company was rebranded and absorbed into Ethicon. Johnson & Johnson Chairman of the Board Robert Wood Johnson published Or Forfeit Freedom in 1947. The book outlined that businesses need to develop sustainable methods of using natural resources for the future of business and the planet. In 1955, Ethicon developed a micro point reverse--‐cutting ophthalmic needle attached to the suture. Micro-point surgical needles and sutures allowed for advances in modern vision surgery. In 1956, the company open its first Asia-based operating company in the Philippines. The following year, an operating company opened in India. In 1959, Johnson & Johnson acquired McNeil Laboratories. A year later, the company sold Tylenol for the first time without a prescription. In the same year, Cilag Chemie joined Johnson & Johnson as Cilag. In 1961, Janssen Pharmaceutica was acquired by Johnson & Johnson. Janssen Pharmaceutica was founded in 1953 by Belgian scientist Dr. Paul Janssen. In 1963, Philip B. Hofmann succeeded Robert Wood Johnson as Chairman and CEO. He was the first non-Johnson family member to become chief executive. Hofmann also helped found the Robert Wood Johnson Foundation. In the same year, the Food and Drug Administration approved a synthetic hormone contraceptive pill, Ortho-Novum. In 1965, Johnson & Johnson acquired Codman & Shurtleff. The acquired company produced neurovascular devices and neurosurgery technologies. In 1968, the company developed the RhoGAM Vaccine. The vaccine prevented Rh hemolytic disease in newborns. In 1969, Ortho Diagnostics, a company subsidiary, launched the Sickledex Tube Test for detecting anemia. The same year, the FDA approved the Johnson & Johnson arterial graft. In 1971, the company launched Hapindex Diagnostic Test, a rapid Hepatitis B test for blood donors. The test was developed to prevent the spread of Hepatitis B through blood transfusions. In 1973, Richard Sellars became Chairman and CEO of Johnson & Johnson. In 1976, James E. Burke became the company’s Chairman and CEO. During Burke’s tenure, he managed the 1982 Tylenol tampering incident. It became a case study on crisis management. Under his leadership, the company recalled 31 million bottles of Tylenol, relaunched the product with a triple tamper-evident seal, and urged consumers not to use if tampered with. These practices became the pharmaceutical and packaged food industry norm. Johnson & Johnson opened operating companies in China and Egypt in 1985. In 1987, Acuvue contact lenses became the first disposable contact lenses available to consumers. The lenses lasted up to one week, reducing the cost of contact lenses. In the same year, the company launched One Touch, a blood glucose monitoring system. In 1989, Ralph S. Larsen was appointed Chairman and CEO of the company. After the Dissolution of the Soviet Union, Johnson & Johnson expanded into eastern Europe. By 1991, the company had a presence in Hungary, Russia, the Czech Republic, and Poland. In the 1990s, the company acquired many familiar consumer health brands that made up the Johnson & Johnson family of companies. These acquisitions included Clean & Clear, Neutrogena, Motrin, and Aveeno. Johnson & Johnson opened an operating company in Israel in 1996. In 1997, Johnson & Johnson acquired Biosense Webster. DePuy was acquired by Johnson & Johnson in 1998, rolling it into the Medtech business group.

2000-present:
William C. Weldon was appointed Chairman and CEO of the company in 2002. In 2003, Ethicon launched Vicryl Plus Antibacterial Sutures. The products prevent post-surgery infection within stitches. In 2006, Johnson & Johnson acquired Pfizer's consumer healthcare business and merged it with its consumer healthcare business group. The acquisition added brands like Listerine, Bengay, and Neosporin to the company’s portfolio. In the same year, Johnson & Johnson’s Janssen Pharmaceuticals, launched Prezista, a protease inhibitor for patients with failed previous HIV therapies.

In 2008, Johnson & Johnson acquired Mentor Corporation for $1 billion and merge its operations into Ethicon. In 2009, the company acquired HealthMedia, later renamed to Health & Wellness Solutions and the Human Performance Institute. In October 2010, J&J acquired Crucell for $2.4 billion. The subsidiary operates as the centre for vaccines, within Johnson & Johnson pharmaceuticals business group. In 2012, Alex Gorsky became Chairman and CEO of Johnson & Johnson. In November 2015, Biosense Webster, Inc. acquired Coherex Medical Inc. expanding the company’s range of treatment options for patients with atrial fibrillation. In 2017, Johnson & Johnson acquired Abbott Medical Optics from Abbott Laboratories for $4.325 billion, adding the new division into Johnson & Johnson Vision Care, Inc. in 2017. The same year, Johnson & Johnson acquired Actelion in a $30 billion deal, the largest ever purchase by the company. After the purchase, Johnson & Johnson spun off Actelion’s research and development unit, into a separate legal entity. In July 2017, Johnson & Johnson Vision Care, Inc acquired TearScience. In September 2017, the company acquired subscription-based contact lens startup Sightbox. In September of the same year Johnson & Johnson Medical GmbH acquired Emerging Implant Technologies GmbH, manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery. In March 2019, the FDA approved esketamine for the treatment of severe depression, which is marketed as Spravato by Janssen Pharmaceuticals. In 2019, Johnson & Johnson announced the release of photochromic contact lenses. The lenses adjust to sunlight and help eyes recover from bright light exposure faster. The lenses contain a photochromic additive that adapts visible light amounts filtered to the eyes and are the first to use such additives. In November 2020, Johnson & Johnson acquired Momenta Pharmaceuticals for $6.5 billion.

In January 2022, Joaqiun Duato became CEO of Johnson & Johnson.

2.

Reason and Request: The COVID-19 subsections of the History section may suffer from WP:RECENT and shared many duplicate sentences with Janssen COVID-19 vaccine Wikipedia article. The subsections give the Janssen COVID-19 vaccine article attribution; thus, some of the content is extraneous. This suggestion also supports reducing the article size. Please replace current sections with proposed sections.

Proposed Covid-19 sections; remove duplicate content from the Janssen COVID-19 vaccine Wikipedia article

Coronavirus (COVID-19) response
Johnson & Johnson committed over $1 billion toward the development of a not-for-profit COVID-19 vaccine in partnership with the Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). Paul Stoffels of Johnson & Johnson said, "In order to go fast, the people of Johnson & Johnson are committed to do this and all together we say we're going to do this not for profit. That's the fastest and the best way to find all the collaborations in the world to make this happen so we commit to bring this at a not-for-profit level."

Janssen Vaccines, in partnership with Beth Israel Deaconess Medical Center (BIDMC), is responsible for developing the vaccine candidate, based on the same technology used to make its Ebola vaccine. The vaccine candidate is expected to enter phase 1 human clinical study in September 2020.

Demand for the product Tylenol surged two to four times normal levels in March 2020. In response, the company increased production globally. For example, the Tylenol plant in Puerto Rico ran 24 hours a day, seven days a week.

In response to the shortage of ventilators, Ethicon, with Prisma Health, made and distributed the VESper Ventilator Expansion Splitter, which uses 3D printing technology, to allow one ventilator to support two patients.

Janssen COVID-19 vaccine
In June 2020, Johnson & Johnson and the National Institute of Allergy and Infectious Diseases (NIAID) confirmed its intention to start a clinical trials of J&J's vaccine in September 2020, with the possibility of Phase 1/2a human clinical trials starting at an accelerated pace in the second half of July.

On 5 August 2020, the US government agreed to pay more than $1 billion to Johnson and Johnson (medical device company) for the production of 100 million doses of COVID-19 vaccine. As part of the agreed-upon deal, the U.S. can order up to 200 million additional doses of SARS-CoV-2 vaccine.

In September 2020, Johnson & Johnson started its 60,000-person phase 3 adenovirus-based vaccine trial. The trial was paused on October 12, 2020, because a volunteer became ill, but the company said it found no evidence that the vaccine had caused the illness and announced on October 23, 2020, that it would resume the trial.

In April 2021, the company reported that its Covid-19 vaccine achieved $100 million sales in the first quarter, accounting for less than 1% of its total revenue.

--Chefmikesf (talk) 19:47, 3 October 2022 (UTC)

New content, some cn tags
, Thanks to there is now a cladogram listing all the branches of J&J. Could you please verify its accuracy? It may fit more logically at the bottom of the Business sectors section, since it parallels the 3 subdivisions there.

Also, there are currently 5 cn tags. Do you have sources for those (currently unsourced) paragraphs? — Grand&#39;mere Eugene (talk) 17:53, 1 November 2022 (UTC)

, I hope you're having a great holiday season with your family. Thanks for pointing this out. I updated most of the tags with sources I found. The chart is wildly outdated, so I need more time to curate all the references to determine how I feel about the table. While searching for the sources, I found minor updates and additions to improve the article. Are you open to reviewing the changes below?--Chefmikesf (talk) 00:34, 28 December 2022 (UTC)


 * It may take me a while-- family/holiday stuff right now... — Grand&#39;mere Eugene (talk) 03:45, 28 December 2022 (UTC)
 * , No worries! Have a great holiday season. Talk to you in the New Year!--Chefmikesf (talk) 21:25, 28 December 2022 (UTC)
 * , Hope you had a great holiday season! Just wanted to check in to see if you had any thoughts on the content. Best --Chefmikesf (talk) 23:24, 30 January 2023 (UTC)
 * I'll work on it this week, promise! — Grand&#39;mere Eugene (talk) 21:31, 13 February 2023 (UTC)
 * ✅. Have you given any more thought to dividing the article? — Grand&#39;mere Eugene (talk) 19:34, 15 February 2023 (UTC)

2.

Reason and Request: The current article lacks content about the company's innovation business unit. Consider adding proposed content below. Add as the second paragraph of the Business sectors section. *See my sandbox for example.

Johnson & Johnson Innovation, LLC (JJI) is a subsidiary of Johnson & Johnson. JJI focuses on early-stage, life science, and technology innovations to advance the company’s research and development pipeline. JJI provides startups with sourcing, infrastructure, and capital equipment at JLABS, financing & venture capital at JJDC, Inc., and collaborations leading to the potential development of medical device technologies, pharmaceuticals, and therapeutics. There are 4 JJI Innovation Centers located in London, Shanghai, Boston (Cambridge) , and the San Francisco Bay Area. There are 13 JLABS incubators located in the Bay Area (San Francisco and South San Francisco), Belgium (Beerse), Boston (Cambridge and Lowell), Houston (TMC) , New York, Philadelphia, San Diego, Shanghai, Toronto, and Washington D.C.

2.

Reason and Request: Update Board of directors, Executive committee and chairman subsections for accuracy.

The current members of the board of directors of Johnson & Johnson for 2022 are: Mary C. Beckerle; D Scott Davis; Ian E. L. Davis; Jennifer A Doudna; Alex Gorsky; Marillyn A. Hewson; Hubert Joly; Mark B. McClellan; Anne M. Mulcahy; A. Eugene Washington; Mark A. Weinberger; Nadja Y. West; and Darius Adamczyk.

The current members of the Executive Committee of Johnson & Johnson are: Joaquin Duato; Vanessa Broadhurst; Peter Fasolo; Liz Forminard; William N. Hait; Ashley McEvoy; Thibaut Mongon; James Swanson; Jennifer Taubert; Kathy Wengel; Joseph J. Wolk.

Joaquin Duato is Chairman and Chief Executive Officer.

Chairmen

 * Robert Wood Johnson I (1887–1910)
 * James Wood Johnson (1910–1932)
 * Robert Wood Johnson II (1932–1963)
 * Philip B. Hofmann (1963–1973)
 * Richard B. Sellars (1973–1976)
 * James E. Burke (1976–1989)
 * Ralph S. Larsen (1989–2002)
 * William C. Weldon (2002–2012)
 * Alex Gorsky (2012–2022)
 * Joaquin Duato (2023-Present)

Johnson & Johnson’s New Logo
I hate the new logo. It was fine just the way it was. Easily recognizable. Now kenvue is the only one carrying the Johnson & Johnson script. Why do you think they made this decision? KAISEAN W. (talk) 18:54, 15 September 2023 (UTC)
 * Concur. I hate it too. But WP policy is to follow, not lead, so we have to use the new logo in this article.
 * To answer your question: The dominant idea in business since the turn of the 21st century is the idea of the core competency. That's why so many conglomerates like United Technologies and General Electric were or are being dismantled. The basic problem is that succession at the highest level of conglomerates has always been messy because there are too few people who can competently manage people around the world across multiple industrial sectors over a sustained period of time, while the pool of competent executives who are excellent in one specific sector is much larger. In the healthcare field, this trend means healthcare conglomerates should become pure-play drug companies riding the bleeding edge in search of the next blockbuster drug, and ditch their relatively stagnant consumer brands. So Pfizer and GSK joined forces to park their consumer brands in Haleon, and J&J spun off Kenvue so what's left can become a pharmaceutical and medical device company.  The change of logo signals the company is shedding their past as a sprawling healthcare conglomerate.  --Coolcaesar (talk) 19:30, 17 September 2023 (UTC)

Merge proposal: Handle-o-Meter to here
Handle-o-Meter isn't notable in itself, but a merge/redirect here could be helpful to readers. Boleyn (talk) 15:51, 17 November 2023 (UTC)


 * Reject-- The Handle-o-Meter article has no secondary sources and I couldn't find any in my search. I'd suggest determining notability for the content first.--Chefmikesf (talk) 22:26, 4 December 2023 (UTC)

Article updates 2023
Hi ,

The article has some outdated content; below are the suggested edits. The proposed improvements can help reduce the size of the article. First, there are some simple edits, such as updating the Board of Directors and Executive Committee. ✅ — Grand&#39;mere Eugene (talk) 21:24, 23 June 2023 (UTC)

The Headquarters and the New Brunswick gentrification section is duplicate content from the Johnson and Johnson Plaza article, and the sentences are poorly sourced. The sourced content in the section fits into the History section, and it would remove the duplicated content. Take a look at the suggestion below.

1. Please Update the Board of Directors and Executive Committee

The current members of the board of directors of Johnson & Johnson for 2023 are Joaquin Duato, Darius Adamczyk, Mary C. Beckerle, D. Scott Davis, Jennifer A. Doudna, Marillyn A. Hewson, Paula A. Johnson, Hubert Joly, Mark B. McClellan, Anne M. Mulcahy, Mark A. Weinberger, and Nadja Y. West.

The current members of the Executive Committee of Johnson & Johnson are Joaquin Duato, Vanessa Broadhurst, Peter Fasolo, Liz Forminard, William N. Hait, Ashley McEvoy, John C. Reed, James Swanson, Jennifer Taubert, Kathy Wengel, and Joseph J. Wolk.

2. Remove the two graphs from Finance section. The graphs are not working due to technical issues.

3. Remove the Headquarters and the New Brunswick gentrification section, then add suggested sentences to the history section.

Existing Content (Headquarters and the New Brunswick gentrification)

The company has historically been located on the Delaware and Raritan Canal in New Brunswick. The company considered moving its Headquarters out of New Brunswick in the 1960s but decided to stay in the town after city officials promised to revitalize downtown New Brunswick by demolishing old buildings and constructing new ones. While New Brunswick lost many historic structures, including the early home of Rutgers University, and most of its historic commercial waterfront to the redevelopment effort, the gentrification did attract people back to New Brunswick. Johnson & Johnson hired Henry N. Cobb from Pei Cobb Freed & Partners to design its new Headquarters. Johnson and Johnson Plaza, in a park across the railroad tracks from the older portion of the Headquarters, is one of tallest buildings in New Brunswick.[ citation needed]

The stretch of Delaware and Raritan canal by the company's Headquarters was replaced by a stretch of Route 18 in the late 1970s, after a lengthy dispute. In 2002, the company released its plan of setting up Asia-Pacific information technology headquarters in New South Wales within five years.

New Content (Move section to the History section)

Move to 1886: Founding of Johnson & Johnson as sentence three

Johnson & Johnson opened its first factory building in the old Janeway and Carpenter factory on Neilson Street in New Brunswick, New Jersey.

Move to 1944-1999: Acquisitions and international expansion as paragraph eight.

In the 1970s, Johnson & Johnson hired Henry N. Cobb from Pei Cobb Freed & Partners to design its new Headquarters. The firm designed Johnson & Johnson Plaza across the railroad tracks from the older section of the Johnson & Johnson campus.

4. Question: Should we remove the tree diagram from the COVID section? It doesn't really make sense in that section, it needs to be updated, and it's adding a lot of unnecessary bytes to the article. Thoughts?


 * I agree, I removed it. — Grand&#39;mere Eugene (talk)

Chefmikesf (talk) 21:01, 22 June 2023 (UTC)

Hi KAISEAN W. and Grand'mere Eugene, There are some significant changes to the company with the split-off and exchange offer. I'm currently working on a proposed sandbox to address all the changes. Would you be open to reviewing the changes later in the week? Thanks in advance---Chefmikesf (talk) 22:07, 22 August 2023 (UTC)


 * Go ahead. I don’t do any heavy changes mainly because of how confusing they are to me. Hard to change the sector wikitable without it collapsing. KAISEAN W. (talk) 22:18, 22 August 2023 (UTC)
 * Okay I got the Wikitable done. KAISEAN W. (talk) 22:30, 22 August 2023 (UTC)
 * I should have time early next week after grandkids leave. — Grand&#39;mere Eugene (talk) 00:28, 23 August 2023 (UTC)
 * Hi @Grand'mere Eugene Here are the suggested edits for the JNJ article. I'm also going to post on the JNJ template box to bring it up to date as well.

✅ — Grand&#39;mere Eugene (talk) 09:57, 30 August 2023 (UTC)


 * @Grand'mere Eugene, the current Lead's last two paragraphs remain from the old Lead. Can you remove them? The content in those paragraphs duplicates the content above it and is outdated with the consumer healthcare split-off. The new data will come out in the following annual report. It's best to remove the content until the annual report is available.--Chefmikesf (talk) 18:40, 5 September 2023 (UTC)
 * ✅ — Grand&#39;mere Eugene (talk) 19:02, 5 September 2023 (UTC)
 * 1.
 * Reason and Request: Lead is inaccurate and out of date.
 * Current Lead:
 * Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
 * Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $93.8 billion during the calendar year 2021.
 * The company announced in November 2021 that it would split into two publicly traded companies: one focused on consumer products and the other on pharmaceuticals and medical technologies.
 * Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $93.8 billion during the calendar year 2021.
 * The company announced in November 2021 that it would split into two publicly traded companies: one focused on consumer products and the other on pharmaceuticals and medical technologies.


 * Proposed Lead:
 * Johnson & Johnson (J&J) is an American multinational, pharmaceutical, and medical technologies corporation headquartered in New Brunswick, New Jersey and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 40 on the 2023 Fortune 500 list of the largest United States corporations. Johnson & Johnson has a global workforce of approximately 130,000 employees who are led by the company’s current chairman and chief executive officer, Joaquin Duato.
 * Johnson & Johnson was founded in 1886, by three brothers Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson selling ready-to-use sterile surgical dressings. In 2023, the company split off its consumer healthcare business group into a new publicly traded company, Kenvue. The company is exclusively focused on developing and producing pharmaceutical prescription drugs and medical device technologies.
 * Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.
 * 2.
 * Reason and Request:Recent split-off changed the company's structure. Please update the Business sectors according to these suggestions.
 * 1. Business Sectors, Sentence One and Two: Update to one sentence.
 * The company's business is divided into two business sectors: Pharmaceuticals and Medtech.
 * 2. Remove the Consumer Healthcare (1888-2023) section entirely. Add a new paragraph to the History 2000-present section to highlight the history of the Consumer Healthcare Business Sector separation.
 * 3. Add to History, 2000-present section:
 * Johnson & Johnson began the separation of their consumer healthcare business group in November 2021. In September 2022, Johnson & Johnson chose Kenvue as the new name for its Consumer Health business. Kenvue went public through an IPO in May 2023, with Johnson & Johnson maintaining a controlling stake of around 91 percent. On July 24th, 2023, Johnson & Johnson Launched an exchange offer to split-off Kenvue. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.
 * Chefmikesf (talk) 23:35, 29 August 2023 (UTC)
 * Chefmikesf (talk) 23:35, 29 August 2023 (UTC)
 * Chefmikesf (talk) 23:35, 29 August 2023 (UTC)

History section
Hi @Grand'mere Eugene I noticed the last section of the History section got bit unwieldy. Any thoughts on the suggestion?

1. Reason and Request: Patent on tuberculosis-treating drug, bedaquiline History subsection lacks secondary sources. Suggest removing most of the content and the subsection. Once removed, add the content below to the 2000–present subsection in chronological order after the Kenvue content.

2000–present
...9.5% of the outstanding shares of Kenvue common stock.

Johnson & Johnson holds a patent on the tuberculosis-treating drug bedaquiline, with secondary patents in at least 25 out of 43 countries with a high burden of tuberculosis blocking affordable generic versions of the drug, preventing millions of people from accessing the life-saving treatment. Though the patent was set to expire in many countries in 2023, Johnson & Johnson applied to extend the patent. On July 13, 2023, Stop TB Partnership announced that after negotiations with Johnson & Johnson, they had been granted licenses to produce generic versions of the drug.

✅ Good catch. — Grand&#39;mere Eugene (talk) 01:06, 5 December 2023 (UTC)
 * Thanks — Grand&#39;mere Eugene!--Chefmikesf (talk) 22:32, 6 December 2023 (UTC)